Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study by Jørgensen, Casper H et al.
ORIGINAL INVESTIGATION Open Access
Effects of oral glucose-lowering drugs on long
term outcomes in patients with diabetes mellitus
following myocardial infarction not treated with
emergent percutaneous coronary intervention -
a retrospective nationwide cohort study
Casper H Jørgensen
1*, Gunnar H Gislason
1, Charlotte Andersson
1, Ole Ahlehoff
1, Mette Charlot
1, Tina K Schramm
1,
Allan Vaag
2, Steen Z Abildstrøm
3,4, Christian Torp-Pedersen
1,5, Peter R Hansen
1
Abstract
Background: The optimum oral pharmacological treatment of diabetes mellitus to reduce cardiovascular disease
and mortality following myocardial infarction has not been established. We therefore set out to investigate the
association between individual oral glucose-lowering drugs and cardiovascular outcomes following myocardial
infarction in patients with diabetes mellitus not treated with emergent percutaneous coronary intervention.
Materials and methods: All patients aged 30 years or older receiving glucose-lowering drugs (GLDs) and
admitted with myocardial infarction (MI) not treated with emergent percutaneous coronary intervention in
Denmark during 1997-2006 were identified by individual-level linkage of nationwide registries of hospitalizations
and drug dispensing from pharmacies. Multivariable Cox regression models adjusted for age, sex, calendar year,
comorbidity, and concomitant pharmacotherapy were used to assess differences in the composite endpoint of
non-fatal MI and cardiovascular mortality between individual GLDs, using metformin monotherapy as reference.
Results: The study comprised 9876 users of GLDs admitted with MI. The mean age was 72.3 years and 56.5% of
patients were men. A total of 3649 received sulfonylureas and 711 received metformin at admission. The average
length of follow-up was 2.2 (SD 2.6) years. A total of 6,171 patients experienced the composite study endpoint. The
sulfonylureas glibenclamide, glimepiride, glipizide, and tolbutamide were associated with increased risk of
cardiovascular mortality and/or nonfatal MI with hazard ratios [HRs] of 1.31 (95% confidence interval [CI] 1.17-1.46),
1.19 (1.06-1.32), 1.25 (1.11-1.42), and 1.18 (1.03-1.34), respectively, compared with metformin. Gliclazide was the only
sulfonylurea not associated with increased risk compared with metformin (HR 1.03 [0.88-1.22]).
Conclusions: In patients with diabetes mellitus admitted with MI not treated with emergent percutaneous
coronary intervention, monotherapy treatment with the sulfonylureas glibenclamide, glimepiride, glipizide, and
tolbutamide was associated with increased cardiovascular risk compared with metformin monotherapy.
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Patients with diabetes mellitus (DM) have increased risk
of cardiovascular disease (CVD) and worse outcomes
after surviving an adverse cardiovascular event [1-3].
Prevention and management aimed at reducing CVD in
DM include lifestyle interventions, cardiovascular phar-
macotherapy (treatment of hypertension, dyslipidemia
etc.), and glucose-lowering drugs (GLDs) [4]. Whether
intensive control of blood glucose levels improves CVD
has been intensively studied during the past few years
and the optimum pharmacological treatment to reduce
hyperglycaemia and CVD has not been established
[5-10]. In particular, the report from the University
Group Diabetes Program (UGDP) almost 40 years ago
of increased cardiovascular mortality in DM patients
receiving the first-generation sulfonylurea tolbutamide
has not been conclusively refuted [11,12]. In contrast
to the UGDP results, however, the UK Prospective
Diabetes Study (UKPDS) found no increased mortality
with sulfonylureas compared to conventional treatment
primarily with diet alone, but suggested reduced risk of
MI, stroke, and total mortality with metformin com-
pared to treatment with diet, sulfonylurea or insulin, in
obese patients with type 2 DM [13]. A more recent 10-
year follow-up of UKPDS even suggested that sulfony-
lureas and insulin may be associated with reduced CVD
comparable to the effects of metformin [14].
Sulphonylureas may inhibit myocardial precondition-
ing and theoretically, this detrimental effect may be of
more importance in patients with MI undergoing emer-
gent (primary) percutaneous coronary intervention (PCI)
[15,16]. Furthermore, on-going treatment with metfor-
min has been considered as a contraindication for intra-
venous contrast exposure (e.g., during emergent PCI)
because of a perceived risk of lactic acidosis, although
this contention is increasingly debated [17,18]. In view
of these uncertainties regarding the safety of oral GLDs
in patients with MI, we recently examined long term
outcomes in diabetes patients with MI that underwent
emergent PCI, and found that glibenclamide, but not
other sulphonylurea agents, was associated with
increased mortality and morbidity compared to metfor-
min [19]. Patients undergoing emergent PCI only repre-
sent a fraction of the MI population, and the present
study was therefore undertaken to investigate effects of
oral GLDs on long term outcomes in patients with MI
that did not undergo emergent PCI.
Materials and methods
National registers
In Denmark, all citizens have a unique personal civil
registration number that enables individual linkage of
information across nationwide registers. The National
Patient Register keeps information of all admissions and
invasive therapeutic procedures performed in Danish
hospitals since 1978. Each admission is registered by a
primary, and, if appropriate, one or more secondary
diagnoses, coded according to the 10
th revision of the
International Classification of Diseases (ICD-10). The
diagnosis of acute MI has previously been validated in
the National Patient Registry with a specificity of 93%
[20]. The Danish Register of Medicinal Product Statistics
(National Prescription Register) holds information on all
prescriptions dispensed from Danish pharmacies since
1995. Drugs are registered according to the international
Anatomical Therapeutical Chemical (ATC) classifica-
tion. Because of the national health care reimbursement
scheme of drug expenses, pharmacies in Denmark are
required to register all dispensed prescriptions ensuring
complete registration [21]. The civil registration system
holds information on vital status for all citizens, and all
deaths are registered within 14 days of occurrence. Pri-
mary and contributing causes of mortality are registered
in the National Causes of Mortality Register according
to the ICD-10.
Study population and GLDs
Patients aged 30 years or older admitted to Danish hos-
pitals during 1997-2006 with a diagnosis of MI (ICD-10
codes I21-I22) were identified from the National Patient
Registry. In this study, we included all patients admitted
with MI that did not undergo percutaneous coronary
intervention (PCI) procedures during the first 48 hours
after admission. PCI was detected by use of the Danish
Health Care Classification System codes KFNG02 and
KFNG05. Patients with DM were identified as indivi-
duals claiming at least one prescription for GLDs (oral
agents or insulin) in the period ≤ 180 days prior to
admission with MI. Treatment received in this period
was defined as baseline treatment and used as a fixed
variable in the analyses. By determination of the amount
of dispensed tablets, their strengths, and dispensing time
intervals for up to 7 consecutively claimed prescriptions
after discharge, an individually adjusted coverage of
drug treatment at the time of a study endpoint (see
below) was calculated for all GLDs. This method has
been described in details previously [22]. Patients with
DM were subdivided into groups receiving specific GLD
monotherapies, combinations of two or more oral
agents and/or insulin, or no GLD, respectively. All
claimed prescriptions for insulin (ATC A10A), metfor-
min (ATC A10B), glimepiride (ATC A10BB12), gliben-
clamide, known as glyburide in the U.S. and Canada
(ATC A10BB01), glipizide (ATC A10BB07), gliclazide
(ATC A10BB09), and tolbutamide (ATC A10BB03) were
included. DM patients on dietary treatment alone or
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≤ 180 days prior to the admission with MI were not
included. Patients requiring insulin monotherapy are
more likely to have type 1 DM and a more advanced
stage of diabetes compared with patients receiving oral
GLDs. We therefore included patients treated with insu-
lin both to test the a priori assumption that these sub-
jects would have the greatest risk of CVD, but also to
allow for identification of patients that changed to insu-
lin during the follow up period and to allow for indiscri-
minate detection of all GLDs. Only 12 patients received
alpha-glucosides in monotherapy and they were there-
fore excluded from the analysis. Thiazolidinediones are
not recommended as monotherapy in Denmark and
during the study period no patients were identified
receiving these drugs in monotherapy.
Concomitant pharmacotherapy, comorbidity and
socioeconomic status
All variables listed below were selected a priori. We
examined concomitant cardiovascular pharmacotherapy
as determined by prescriptions claimed ≤ 180 days prior
to the index MI to describe concomitant pharmacother-
apy at baseline and furthermore prescriptions claimed
≤ 90 days after the index admission. The following
drugs were identified: angiotensin converting enzyme
(ACE) inhibitors and angiotensin-2 receptor blockers
(ATC C09), b-blockers (ATC C07) spironolactone (ATC
C03D), loop diuretics (ATC C03C), clopidogrel (ATC
B01AC04), vitamin K-antagonists (ATC B01AA), and
statins (ATC A10A). Concomitant pharmacotherapy was
used as fixed variables in both types of analyses
performed. Co-morbidity was defined according to the
modified Ontario Myocardial Infarction Mortality
Prediction Rules by diagnoses from the index admission
and 1 year prior to admission (ICD-10 codes) [23]. The
diagnoses used were congestive heart failure, cardiac
dysrhythmias, pulmonary oedema, shock, cerebrovascu-
lar disease, DM with chronic complications, acute renal
failure, chronic renal failure, and cancer. Socioeconomic
status was defined by the individual average yearly gross
income during a 5-year period before the index MI.
Patients were divided into quartiles according to their
income.
Endpoints
The primary endpoint of the study was a composite of
nonfatal MI (ICD-10 codes I21-I22) and cardiovascular
mortality, defined as death with CVD (ICD-10 codes
I00-I99) listed as a primary or contributing cause of
death. Secondary endpoints were cardiovascular mortal-
ity and all-cause mortality, respectively. Nonfatal MI
was defined as a subsequent admission with MI more
than 30 days after the index admission.
Statistical Analysis
Multivariable Cox proportional-hazard regression ana-
lyses were used to asses risk with individual GLDs.
Exposure to GLDs was included as a fixed variable for
baseline treatment and time-dependent variable for ana-
lyses performed at time of endpoint. Further, time-
dependents analyses of adverse CVD events after MI
patients were also performed such that patients were
only considered at risk when taking the respective GLD.
All Cox models were censored for deaths resulting from
causes not related to the endpoints of interest. For the
composite endpoint, we estimated the time to the first
event (nonfatal MI or cardiovascular mortality). Cox
analyses were adjusted for age, sex, socioeconomic sta-
tus, calendar year, concomitant pharmacotherapy and
co-morbidity. For all analyses, metformin was used as
reference. The proportional-hazard assumption was
tested specifying both the survival function versus time,
as well as the log(-log(survival) versus log (time) show-
ing parallel curves satisfying the assumption [24]. The
continuous variables age and lifetime were also tested
and found to be linear. The models were tested for lack
of interactions and found to be valid. All statistical
calculations were performed with the SAS statistical
software package, version 9.1 (SAS Institute Inc, Cary,
North Carolina).
Ethics
The Danish Data Protection Agency approved the study
(No. 2007-41-1667). Retrospective register studies where
data are processed in a form where individuals can not
be identified, do not require ethical approval in Den-
mark [25].
Results
During the study period (1997-2006), 94,808 patients
where admitted with MI of which 10,808 claimed
glucose-lowering drugs < 180 days prior to the date of
admission. After exclusion of patients receiving emer-
gent PCI during the first 2 days of admission, the final
study population consisted of 9,876 patients. The base-
line characteristics of the cohort are presented in Table
1. The mean age at admission was 72.3 years and 56.5%
of patients were men. The average length of follow-up
was 2.2 (SD 2.6) years. By calculating the time from first
claimed prescription of GLDs to inclusion in the study
with MI, the mean duration of diabetes was 4.8 years
(SD 3.0), although information on medical therapy was
only available from 1995 and onwards. Factors known
to affect mortality, such as age, sex and co-morbidity
were similar in the GLD exposure groups except for
patients receiving metformin, who were younger, had
less congestive heart failure, pulmonary oedema, and
chronic renal failure, and were more likely to receive
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eas. Comparisons of patients treated with individual sul-
fonylureas showed that patients receiving gliclazide were
younger and patients receiving tolbutamide were older
and had more cerebrovascular disease.
Mortality and nonfatal MI
Kaplan-Meier analyses were used to calculate survival
probability estimates of 0.440, 0.366, and 0.375 for car-
diovascular mortality, all-cause mortality, and rates of
nonfatal MI and cardiovascular mortality, respectively,
for the entire study period. Figure 1 shows Kaplan-
Meier curves for GLD treatment received as monother-
apy ≤ 180 days prior to MI for the composite endpoint
of non-fatal MI and cardiovascular mortality one year
post MI, with all sulfonylureas grouped as one pharma-
cologic class. Time-dependent Cox proportional-hazards
regression analyses only having patients at risk while
using medication showed increased risk of cardiovascu-
lar mortality, nonfatal MI and cardiovascular mortality,
and all-cause mortality with glibenclamide, glimepiride,
glipizide, and tolbutamide, compared with metformin
(Table 2). As indicated in Figure 2A,B and 2C, gliclazide
was not associated with increased risk compared with
metformin.
Comparisons of hazard ratios (HRs) with individual
sulfonylureas at baseline and at the time of a study
endpoint, respectively, showed similar results for all
GLDs apart from glimepiride and tolbutamide. Glime-
piride was associated with greater risk when analyzed
at the time of endpoints and tolbutamide was exclu-
sively associated with increased all-cause mortality
when analyzed at the time of a study endpoint. Insulin
treatment was associated with the greatest risk for all
endpoints (Table 2 and 3). Treatment guidelines chan-
ged during the study period and additional analyses
Table 1 Baseline characteristics
Total Metformin Insulin Glibenclamide Glimepiride Glipizide Gliclazide Tolbutamide Combo*
(%) 9876 711(7.2) 2889(29.3) 1136(11.5) 1180(12.0) 569(5.8) 221(2.2) 543(5.5) 2615(26.5)
Age (mean [SD) 72.3(11.2) 68.7(11.4) 70.5(12.1) 75.3(10.3) 74.7(10.5) 75.6(10.2) 73.9(10.4) 76.1(10.6) 71.4(10.5)
Men (%) 5582 (56.5) 439(7.9) 1476(26.4) 666(11.9) 712(12.8) 323(5.8) 134(2.4) 300(5.4) 1522(27.3)
Age; men (mean [SD) 70.3(11.2) 66.8(11.0) 68.2(12.0) 73.1(10.6) 72.7(10.6) 73.5(10.6) 72.4(11.0) 73.8(11.1) 69.6(10.3)
Women (%) 4294(43.5) 272(6.3) 1413(32.9) 470(11.0) 468(10.9) 246(5.7) 87(2.0) 243(5.7) 1093(25.5)
Age; women (mean [SD) 75.0(10.7) 71.9(11.2) 73.0(11.8) 78.4(9.1) 77.9(9.6) 78.4(8.9) 76.0(9.0) 78.9(9.1) 73.9(10.1)
Study inclusion period
1997-1998 2034(20.6) 57(2.8) 566(27.8) 410(20.2) 56(2.8) 207(10.2) 43(2.1) 213(10.5) 482(23.7)
1999-2000 1898(19.2) 84(4.3) 557(29.4) 273(14.4) 200(10.5) 157(8.3) 44(2.3) 128(6.7) 451(23.8)
2001-2002 2310(23.4) 175(7.6) 684(29.6) 229(9.9) 328(14.2) 111(4.8) 44(1.9) 116(5.2) 620(26.8)
2003-2004 2031(20.6) 203(10.0) 581(28.6) 153(7.5) 349(17.2) 61(3.00) 61(3.00) 57(2.8) 564(27.8)
2005-2006 1603(16.2) 192(12.0) 501(31.3) 71(4.4) 247(15.4) 33(2.1) 29(1.8) 29(1.8) 498(31.1)
Comorbidity
Congestive heart failure 1963(19.9) 104(14.6) 621(21.5) 205(18.1) 239(20.3) 101(17.8) 44(19.9) 113(20.8) 536(20.5)
Cardiac dysrhythmias 1264(12.8) 81(11.4) 381(13.2) 134(11.8) 175(14.8) 66(11.6) 36(16.3) 72(13.3) 317(12.1)
Pulmonary oedema 332(3.4) 13(1.8) 99(3.4) 51(4.5) 19(1.6) 21(3.7) 6(2.7) 30(5.5) 93(3.6)
Shock 286(2.9) 14(2.0) 111(3.8) 27(2.4) 32(2.7) 17(3.0) 5(2.3) 12(2.2) 68(2.6)
Cerebrovascular disease 927(9.4) 51(7.2) 302(10.5) 85(7.5) 116(9.8) 45(7.9) 16(7.2) 67(12.3) 244(9.3)
Diabetes mellitus with
chronic complications
3830(38.8) 193(27.1) 1627(56.3) 26662(23.1) 364(30.9) 142(25.0) 62(28.1) 151(27.8) 1023(39.1)
Acute renal failure 213(2.2) 13(1.8) 108(3.7) 21(1.9) 13(1.1) 10(1.8) 5(2.3) 9(1.7) 34(1.3)
Chronic renal failure 267(2.7) 7(1.0) 150(5.2) 23(2.0) 33(2.8) 7(1.2) 3(1.4) 11(2.0) 33(1.3)
Cancer 465(4.7) 22(3.1) 162(5.6) 61(5.4) 64(5.4) 35(6.2) 9(4.1) 18(3.3) 92(3.5)
Concomitant medication
ACE
† inhibitors or ARBs
‡ 4515(45.7) 344(48.4) 1543(53.4) 354(31.2) 518(43.9) 195(34.3) 90(40.7) 173(31.9) 1291(49.4)
b-Blockers 2319(23.5) 181(25.5) 642(22.2) 273(24.0) 315(26.7) 125(22.0) 51(23.1) 97(17.9) 635(24.3)
Oral anticoagulants 591(6.0) 40(5.6) 171(5.9) 43(3.8) 84(7.1) 23(4.0) 23(10.4) 30(5.5) 176(6.7)
Loop diuretic agents 4188(42.4) 208(29.3) 1486(51.4) 416(36.6) 466(39.5) 216(38.0) 87(39.4) 216(39.8) 1092(41.8)
Spironolactone 783(7.9) 49(6.9) 267(9.2) 48(4.2) 107(9.1) 36(6.3) 15 (6.8) 29(5.3) 230(8.8)
Statins 2031(20.6) 218(30.7) 609(21.1) 106(9.3) 260(22.0) 53(9.3) 34(15.4) 50 (9.2) 697(26.7)
*Combo = combinations of two or more GLDs.
†ACE = angiotensin converting enzyme
‡ARB = angiotensin II receptor blockers. Only patients receiving
monotherapy at baseline at the time of a study end point were examined. Patients receiving insulin and combination treatment were included in the table
allowing for changes in treatment during the study period. 12 patients received acarbose treatment and were excluded from further analysis.
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January 31, 2001, to identify whether time of admission
would compromise the results found for the entire
period. No statistically significant interactions with
individual GLD treatments and time of admission were
found.
The use of metformin and sulfonylureas before and
after MI was very consistent. For patients receiving met-
formin prior to MI, 82.4% of the survivors claimed a new
prescription for metformin. For patients receiving sulfo-
nylureas, 94.2% of survivors claimed a new prescription
for a sulfonylurea.
Figure 1 Kaplan-Meier curves for the composite endpoint of cardiovascular mortality and non-fatal myocardial infarction (MI) one
year after index MI. Treatment groups were baseline glucose-lowering drug monotherapy ≤ 180 days prior to MI.
Table 2 Hazard ratios for studied end points according to treatment at time of a study endpoint
Glucose-lowering drug Cardiovascular mortality Composite of cardiovascular
mortality and non-fatal MI
All-cause mortality
HR 95% CI HR 95% CI HR 95% CI
Metformin 1 1 1
Insulin 1.49 1.34-1.66 1.38 1.25-1.52 1.50 1.35-1.65
Glibenclamide 1.37 1.21-1.54 1.31 1.17-1.46 1.34 1.19-1.50
Glimepiride 1.32 1.17-1.48 1.19 1.06-1.32 1.30 1.16-1.45
Glipizide 1.33 1.16-1.52 1.25 1.11-1.42 1.30 1.14-1.48
Gliclazide 1.10 0.92-1.32 1.03 0.88-1.22 1.06 0.90-1.26
Tolbutamide 1.22 1.06-1.41 1.18 1.03-1.34 1.21 1.06-1.38
All sulfonylureas 1.28 1.14-1.44 1.20 1.08-1.33 1.25 1.13-1.40
Hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse cardiovascular end points according to glucose-lowering drug (monotherapy) at the time of a
study endpoint. Time-dependent Cox analyses were performed with adjustments for age, sex, socioeconomic status, calendar year, concomitant
pharmacotherapy, and comorbidity. MI = Myocardial infarction.
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The current study is, to the best of our knowledge, the
first to compare on a nation-wide scale the outcomes
after MI in patients with DM treated with different
GLDs that did not undergo emergent PCI. We found
that after MI, patients treatedw i t hs e l e c t e ds u l f o n y l u r -
eas including glibenclamide, glimepiride, glipizide, and
tolbutamide had increased risk of cardiovascular mortal-
ity and nonfatal MI, cardiovascular mortality, and all-
cause mortality, respectively, compared to patients
receiving metformin. Gliclazide was the only sulfony-
lurea consistently not associated with increased risk of
adverse cardiovascular events. The results contribute to
data indicating that sulphon y l u r e a sm a yb ea s s o c i a t e d
with adverse cardiovascular events in patients with MI
and they suggest that metformin should generally not be
discontinued in these patients.
Sulphonylureas: Pharmacological effects and tissue
specificities
The primary pharmacological action of sulfonylureas is
closure of KATP channels in the pancreatic b-cell mem-
brane, which depolarizes the cell and triggers insulin
release. However, KATP channels in coronary vascular
smooth muscle cells and cardiomyocytes play important
roles in control of the coronary blood flow and the sig-
nalling cascades underlying myocardial ischemic precon-
ditioning [15,26,27]. In this regard, the affinity of
individual sulfonylureas for pancreatic and cardiac KATP
channels differs substantially. For example, glibenclamide
in clinically relevant concentrations can reduce myocar-
dial protection afforded by preconditioning, whereas
newer sulfonylureas such as glimepiride and gliclazide do
not appear to display these cardiac effects [28-34].
Indeed, glibenclamide (but not other sulfonylureas) was
Figure 2 A: Risk of cardiovascular mortality and non-fatal myocardial infarction (MI), B: risk of cardiovascular mortality, and C: risk of
all-cause mortality associated with glucose-lowering drug monotherapy. Time-dependent Cox analyses were performed with adjustments
for age, sex, socioeconomic status, calendar year, concomitant medication and co-morbidity. Analyses for both individual sulfonylureas and
sulfonylureas grouped as one pharmacological class were performed.
Table 3 Hazard ratios for studied end points according to treatment at baseline
Glucose-lowering drug Cardiovascular mortality Composite of cardiovascular
mortality and non-fatal MI
All-cause mortality
HR 95% CI HR 95% CI HR 95% CI
Metformin 1 1 1
Insulin 1.47 1.29-1.68 1.46 1.29-1.66 1.47 1.30-1.66
Glibenclamide 1.31 1.13-1.51 1.34 1.17-1-54 1.26 1.10-1.44
Glimepiride 1.15 1.00-1.33 1.15 1.01-1.32 1.14 1.00-1.31
Glipizide 1.19 1.01-1.40 1.24 1.06-1.44 1.18 1.01-1.37
Gliclazide 1.04 0.83-1.30 1.09 0.89-1.35 1.00 0.81-1.23
Tolbutamide 1.19 1.01-1.40 1.22 1.05-1.43 1.16 0.99-1.35
All sulfonylureas 1.20 1.05-1.37 1.22 1.08-1.38 1.17 1.04-1.32
Hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse cardiovascular end points according to glucose-lowering drug (monotherapy) at baseline.
Time-dependent Cox analyses were performed with adjustments for age, sex, socioeconomic status, calendar year, concomitant pharmacotherapy, and
comorbidity. MI = Myocardial infarction.
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treatment algorithm for initiation and adjustment of
combined pharmacologic treatment for hyperglycaemia
in patients with DM [35], and consistent with these
results, glibenclamide was the sulfonylurea associated
with the greatest risk in our study. In agreement with the
current results, we recently reported that in DM patients
with MI that underwent emergent PCI, i.e., the compli-
mentary diabetic MI population for the present study,
glibenclamide was associated with increased risk of cardi-
ovascular mortality, cardiovascular mortality and nonfatal
MI, and all-cause mortality, respectively, compared to
patients receiving metformin [17]. In that study, the HR
for the composite of cardiovascular death and nonfatal
MI with glibenclamide compared to metformin was
approximately twice the HR found in the current study,
while other sulphonylurea drugs were not associated with
increased risk, although significant heterogeneity between
individual agents was observed [17]. At present, there-
fore, it is unclear whether adverse cardiovascular out-
comes associated with glibenclamide in DM patients with
MI, represent a pharmacological class effect of sulphony-
lureas. Gliclazide is highly selective for pancreatic KATP
channels and was not associated with increased risk of
adverse cardiovascular events in the present study. Inter-
estingly, disparate cardiac effects of glibenclamide and
gliclazide on myocardial preconditioning have been
demonstrated in patients with stable angina pectoris,
where increased exercise tolerance conferred by exercise-
induced ischemic preconditioning was abolished by glib-
enclamide, but was somewhat preserved with gliclazide
[32]. Moreover, experimental studies have indicated that
gliclazide may prevent or retard the development of
atherosclerosis by exerting antioxidant effects and by
reducing monocyte adhesion to vascular cells [36]. We
found that tolbutamide was associated with increased
risk compared to metformin but the risk with tolbuta-
mide was not significantly different from that of treat-
ment with gliclazide (p > 0.05 for all endpoints).
Tolbutamide and gliclazide appear to be highly pancrea-
tic b-cell-selective compared with glimepiride and gliben-
clamide [27]. Our finding of similar risk associated with
tolbutamide and gliclazide therefore supports the hypoth-
esis that the differences in outcomes after MI with differ-
ent sulfonylureas may be explained, in part, by
differences in KATP channel tissue specificities.
Metformin vs. sulphonylureas
The therapeutic effects of metformin and sulfonylureas
are mediated through entirely different mechanisms.
The glucose-lowering effects of metformin are mainly a
consequence of reduced hepatic gluconeogenesis and
increased insulin-stimulated glucose uptake in skeletal
muscle and fat tissue [37]. Metformin appears to
improve vascular function, exert favourable effects on
lipid metabolism, and reduce hypercoagulability and pla-
telet reactivity in patients with DM [37]. These effects
may have contributed to the improved cardiovascular
mortality observed here in patients receiving metformin
compared with sulfonylureas. After MI, patients may be
advised to change GLDs, e.g., discontinue metformin
because of concern for risk of lactic acidosis, congestive
heart failure, and renal impairment, or discontinue sul-
fonylureas due to a perceived risk of impairing myocar-
dial preconditioning. Our current results in patients
with MI that did not undergo PCI within the first48
hours after admission, however, showed that the use of
GLDs was relatively consistent before and after the
event, indicating that physicians and patients generally
adhere to their established GLDs and are not markedly
influenced by the aforementioned concerns. Importantly,
no adverse cardiovascular endpoints were associated
with continuation of metformin in these patients.
A recently published study comparing outcomes with
sulfonylureas and metformin in patients with DM
included in a large UK general practice research data-
base found that sulfonylureas were associated with
increased risk of first-time MI and all-cause mortality
[38]. This increased risk, however, was not statistically
significant after adjustments for multiple confounders
possibly because of a relatively small sample size. In our
study, we exclusively analyzed data from individuals
with complete information on all examined variables,
and we consistently found an increased risk with sulfo-
nylureas regardless of adjustments for covariates. In
aggregate, the evidence therefore suggests an unfavour-
able cardiovascular risk profile of sulfonylureas com-
pared with metformin.
Strengths and limitations
The main strength of this study was the nationwide con-
secutive patient registries, the contemporary data collec-
t i o n ,t h el a r g es a m p l ec o m p r i s i n gn e a r l y1 0 , 0 0 0p a t i e n t s ,
the assessment of important clinical outcomes, and the
use of pharmacy dispensations and not prescriptions
alone, i.e., with the latter better reflecting true as opposed
to intended drug use. We hereby avoided selection bias
otherwise arising from inclusion of only subgroups of
patients or patients from selected hospitals, medical
centres, or health care systems. Furthermore, the cohort
comprised patients both in and out of the labour market.
In Denmark, a government-financed health care system
ensures free and equal access to health care for all inhabi-
tants. The main study limitation is inherent to the obser-
vational nature of the study design. Although appropriate
adjustments were made for comorbidity, socioeconomic
factors and co-medication, the effect of unmeasured
confounders cannot be excluded. The registers did not
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Page 7 of 9include information on the exact level of drug adherence
and other clinical characteristics, e.g., presence of prein-
farction angina, blood glucose levels, exact diabetes dura-
tion, cholesterol levels, smoking habits and body mass
index, that could have given a more detailed picture of
patient risk profiles. Furthermore, the codes in the
National Patient Registry cannot discriminate between
MI with or without ST segment elevation. Although pri-
mary PCI was quickly established on a national scale
after 2002-3 for patients with ST segment elevation MI
following the results of the Danish Multicenter Rando-
mized Study on Fibrinolytic Therapy versus Coronary
Angioplasty in Myocardial Infarction (DANAMI-2) trial
[39], MI patients in the present study were a mixture of
subjects with or without ST segment elevation on the
presenting ECG, and the ratio of these two MI types
changed during the study period, i.e., with a larger frac-
tion of patients with ST segment elevation MI that
received fibrinolytic treatment on admission in the early
study period, and a predominant population of non-ST
segment MI patients in the later study period. Specific
effects of GLDs in MI patients with or without ST seg-
ment elevation therefore require further investigation,
but it is notable that the results of our previous study of
outcomes with different GLDs in MI patients that under-
went emergent PCI were comparable to the current data
[17]. We also cannot exclude the possibility that the
slightly higher proportion of patients discontinuing met-
formin as opposed to sulfonylurea after MI may preferen-
tially have included those with the most severely reduced
left ventricular function and adverse prognosis, but it
seems highly unlikely that such confounding would sig-
nificantly influence our results. It should also be noted
that the study cohort was homogeneous in terms of eth-
nicity and our findings may not be applicable to other
populations. Moreover, metformin is the advocated drug
of choice in overweight patients with type 2 DM and it is
possible that it was given preferentially to patients with
milder disease. Finally, DM in itself may compromise the
capacity for preconditioning and the adverse cardiovascu-
lar effects of the analyzed sulfonylureas may have been
dependent on other mechanisms than inhibition of pre-
conditioning [40,41].
Conclusions
In conclusion, the current study of cardiovascular out-
comes with different GLDs in DM patients with MI that
did not undergo emergent PCI showed that glibencla-
mide, glimepiride, glipizide, and tolbutamide were asso-
ciated with increased risks of cardiovascular mortality
and nonfatal acute MI, cardiovascular mortality, and all-
cause mortality, respectively, compared to treatment
with metformin. Gliclazide was not associated
with increased risk of adverse cardiovascular events
compared to metformin. Different affinities of individual
sulphonylureas for pancreatic and cardiac KATP channels
may have contributed to these findings. Further studies
of the cardiovascular safety of sulphonylureas are war-
ranted and the results indicate that metformin should
not be discontinued following MI in patients with DM.
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